[ad_1]
Uğur Şahin and Özlem Türeci, CEO of BioNTech, spoke with Der Spiegel, one of the most prestigious magazines in Germany.
“OTHER VACCINES MAY BE A PROBLEM UNTIL YOU ARRIVE”
Uğur Şahin gave a warning to the international public by relaying the current situation regarding Kovid-19 vaccines. Şahin said that due to the lack of approved vaccines currently available on the market, there may be a large gap in the production and distribution process. Speaking with Der Spiegel, Şahin said: “Until other vaccines are approved, there may be gaps in the supply of our vaccine. The situation does not look very good at the moment. There is a gap in the market because there is a lack of approved vaccines and we are trying to fill this with our vaccines. It may. there will be problems until other vaccines arrive. “ said.
Its development will save millions of lives: read how it went with SPIEGEL + #Biontech– Bosses Özlem Türeci and Uğur Şahin live and work what success means to them and what they plan to do next. https://t.co/4bdziXZ2JZ
– DER SPIEGEL (@derspiegel) January 1, 2021
“IT CAN NEUTRALIZE THE MUTATION”
By stating that the European Union (EU) has slow approval for the Pfizer / BioNTech vaccine and has placed a small number of orders, there may be problems with the vaccines across the EU, Şahin said. “The vaccine we have developed can combat the mutated virus first detected in the UK. We are still testing whether our vaccine will also neutralize this mutated strain. More comprehensive results will be obtained.” used the expression. He stated that if the mutated virus is strong, they can change the vaccine in 6 weeks, but stressed that in such a case, they should get approval again.
ÖZLEM TÜRECİ: AFTERNOON AFTERNOON
Speaking to Spiegel, Özlem Türeci said that the slowness of the EU’s decision-making mechanism is a big mistake. The United States ordered 600 million doses of the BioNTech / Pfizer vaccine in July, while the EU decided to order about half that rate in November. Türeci, “At one point it became clear that we couldn’t deliver the vaccines that quickly. From that point on, it was too late to order the vaccines.” said.
Şahin explained that they are planning to establish a new production plant in Marburg, Germany and said they expect to produce 250 million doses in the first half of the year. Hawk, “Negotiations with producers are ongoing and this issue will be clarified at the end of January. said. Şahin also said that they have plans for the vaccine to be kept at minus 70 degrees Celsius and that the new-generation vaccine can withstand higher temperatures in the late summer months.
[ad_2]
